A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy

Journal of Clinical Psychiatry

Volumn 70, Issue 10, 2009, Pages 1348-1357

  Kane, John M ^a   Correll, Christoph U ^a   Goff, Donald C ^b   Kirkpatrick, Brian ^c   Marder, Stephen R ^d   Vester Blokland, Estelle ^e   Sun, Wei ^e   Carson, William H ^f   Pikalov, Andrei ^f   Assunção Talbott, Sheila ^e  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADULT; AGITATION; AKATHISIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEADACHE; HUMANS; MALE; PIPERAZINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 72849140996     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05154yel     Document Type: Article

References (51)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry. 2002;159(suppl 4):1-50. doi:10.1176/appi.ajp.159.1.1
2. Ng F, Dodd S, Berk M. Combination pharmacotherapy in unipolar depression. Expert Rev Neurother. 2006;6(7):1049-1060. doi:10.1586/14737175.6.7.1049 PubMed
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry. 2004;161(suppl 2):1-56. PubMed
4. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 1999;60(10):649-657. PubMed
5. National Institute for Health and Clinical Excellence. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia [NICE guidance]. http://www.nice.org.uk/cat.asp?c=32878; 2002.
6. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5:26. doi:10.1186/1471-244X-5-26 PubMed
7. Keks NA, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry. 1999;33(6):896-901. doi:10.1046/j.1440-1614.1999.00639.x PubMed
8. Broekema WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharm World Sci. 2007;29(3):126-130. doi:10.1007/s11096-006- 9063-1 PubMed
9. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci. 1999;53(suppl):S35-S40. PubMed
10. Rupnow MF, Greenspan A, Gharabawi GM, et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin. 2007;23(11):2815-2822. doi:10.1185/030079907X233359 PubMed
11. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull. 2002;28(1):105-109. PubMed
12. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457. doi:10.1093/schbul /sbn018 PubMed
13. Miller AL. Polypharmacy in schizophrenia: science, art, and fiction. Curr Psychosis & Ther Rep. 2005;3(2):61-67. doi:10.1007/BF02629423
14. Correll CU. Antipsychotic polypharmacy, part 2: why use 2 antipsychotics when 1 is not good enough? J Clin Psychiatry. 2008;69(5):860-861. PubMed
15. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry. 1998;10(3):113-115. PubMed
16. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry. 1996;57(9):395-397. PubMed
17. Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand. 1999;99(4):305-306 [discussion 306-307]. doi:10.1111/j.1600-0447.1999.tb07230.x PubMed (Pubitemid 29155601)
18. Raskin S, Katz G, Zislin Z, et al. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand. 2000;101(4):334-336. PubMed (Pubitemid 30173586)
19. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573. doi:10.1192/bjp.171.6.569 PubMed (Pubitemid 27527329)
20. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162(1):130-136. doi:10.1176/appi.ajp.162.1.130 PubMed (Pubitemid 40095682)
21. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354(5):472-482. doi:10.1056/NEJMoa053222 PubMed (Pubitemid 43200298)
22. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66(1):63-72. PubMed
23. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1-3):90-94. doi:10.1016/j.schres.2006.12.030 PubMed (Pubitemid 46561216)
24. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res. 2006;84(1):77-89. doi:10.1016/j.schres.2005.12.857 PubMed (Pubitemid 44255718)
25. Wolf J, Janssen F, Lublin H, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial With Aripiprazole in Europe (EU-BETA). Curr Med Res Opin. 2007;23(10):2313-2323. doi:10.1185/030079907X225448 PubMed (Pubitemid 350033433)
26. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients: Schizophrenia Trial of Aripiprazole (STAR) Study. Eur Psychiatry. 2007;22(7):433-443. doi:10.1016/j.eurpsy.2007.03.002 PubMed (Pubitemid 47600616)
27. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389. doi:10.1124/jpet.102.033175 PubMed (Pubitemid 34680462)
28. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411. doi:10.1038/sj.npp.1300203 PubMed (Pubitemid 41070874)
29. Tadori Y, Forbes RA, McQuade RD, et al. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur J Pharmacol. 2008;597(1-3):27-33. doi:10.1016/j.ejphar.2008.09.008 PubMed
30. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002;441(3):137-140. doi:10.1016/S0014-2999(02)01532-7 PubMed (Pubitemid 34626163)
31. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18(3):375-383. doi:10.1177/026988110401800308 PubMed (Pubitemid 39382565)
32. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004;483(1):45-53. doi:10.1016/j.ejphar.2003.10.025 PubMed
33. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1386-1392. doi:10.1016/j.pnpbp.2008.02.010 PubMed (Pubitemid 352033663)
34. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):720-731. PubMed
35. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry. 2008;23(suppl 2):S114-S115. doi:10.1016/j.eurpsy.2008.01.784
36. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835. PubMed
37. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404-1410. doi:10.1176/appi.ajp.2007.06071075 PubMed
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:345-428.
39. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
40. Kay SR, Opler LA, Fizbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health System; 1986.
41. Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201-208. PubMed doi:10.1016/0920-9964(92)90003-N
42. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40. PubMed doi:10.1080/009262300278623
43. Hann DM, Denniston MM, Baker F. Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual Life Res. 2000;9(7):847-854. PubMed doi:10.1023/A:1008900413113
44. Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283-297. PubMed doi:10.1016/j.schres.2003.09.011
45. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3):133-138. PubMed doi:10.1097/00004850-199509000-00017
46. Tandon R, Devellis RF, Han J, et al. IAQ Validation Study Group. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 2005;136(2-3):211- 221. PubMed doi:10.1016/j.psychres.2005.05.006
47. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;45(suppl 212):11-19. doi:10.1111/j.1600-0447. 1970.tb02066.x
48. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:534-537.
49. Barnes TR. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol. 2003;17(4):365-370. PubMed doi:10.1177/0269881103174013
50. Kane JM, Barrett EJ, Casey DE, et al. Metabolic effects of treatment with atypical antipsychotics. J ClinPsychiatry. 2004;65(11):1447-1455. PubMed
51. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113(2):142-147. doi:10.1111/j.1600-0447.2005.00612.x PubMed